Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 765423 in idiopathic pulmonary fibrosis
2025-520658-12-00Phase 2Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing BI 765423 with Placebo to BI 765423 (2 arms). Primary endpoint: Absolute change from baseline in forced vital capacity. Planned start Nov 2025; status: authorised.
02
Drugs
BI-765423
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2025-520658-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520658-12-00.